Paper38540673
Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization.
Fu Y and 3 others. Biomolecules, 2024. Cited by 33 papers, by iCite.
Cite this record
ConductScience Library. Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization. Papers, record 38540673. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38540673
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Macular Degeneration | Major topic |
| Choroidal Neovascularization | Major topic |
| Animals | |
| Humans | |
| Angiogenesis Inhibitors | |
| Vascular Endothelial Growth Factor A | |
| Vascular Endothelial Growth Factors | |
| Cholesterol |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 EY034325 | NEI NIH HHS | United States | R01EY034325 | PubMed and NIH | NIH RePORTER |
| R01 EY033000 | NEI NIH HHS | United States | R01EY033000 | PubMed and NIH | NIH RePORTER |
| P30 EY002520 | NEI NIH HHS | United States | P30EY002520 | PubMed and NIH | NIH RePORTER |
| P30 EY007003 | NEI NIH HHS | United States | P30EY007003 | PubMed | NIH RePORTER |
| 1R01EY033805 1R01EY034325 1R01EY033000 2P30EY002520 P30 EY007003 | NIH HHS | United States | R01EY033805 | PubMed and NIH | NIH RePORTER |
| R01 EY033805 | NEI NIH HHS | United States | R01EY033805 | PubMed and NIH | NIH RePORTER |
References127
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32428913 | Meta-Analysis of the Pharmacogenetics of ARMS2 A69S Polymorphism and the Response to Advanced Age-Related Macular Degeneration. | Ophthalmic Res | 2021 | https://conductscience.org/library/papers/32428913 | PubMed |
| 2 | 31288022 | Real-time OCT guidance and multimodal imaging monitoring of subretinal injection induced choroidal neovascularization in rabbit eyes. | Exp Eye Res | 2019 | https://conductscience.org/library/papers/31288022 | PubMed |
| 3 | 31862695 | Lipid rafts in glial cells: role in neuroinflammation and pain processing. | J Lipid Res | 2020 | https://conductscience.org/library/papers/31862695 | PubMed |
| 4 | 10534470 | Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. | Circulation | 1999 | https://conductscience.org/library/papers/10534470 | PubMed |
| 5 | 25166908 | Endothelium in spots--high-content imaging of lipid rafts clusters in db/db mice. | PLoS One | 2014 | https://conductscience.org/library/papers/25166908 | PubMed |
| 6 | 30649077 | RATES OF EXUDATIVE RECURRENCE FOR EYES WITH INACTIVATED WET AGE-RELATED MACULAR DEGENERATION ON 12-WEEK INTERVAL DOSING WITH BEVACIZUMAB THERAPY. | Retina | 2020 | https://conductscience.org/library/papers/30649077 | PubMed |
| 7 | 30849371 | VEGF in Signaling and Disease: Beyond Discovery and Development. | Cell | 2019 | https://conductscience.org/library/papers/30849371 | PubMed |
| 8 | 27330279 | Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. | Drug Des Devel Ther | 2016 | https://conductscience.org/library/papers/27330279 | PubMed |
| 9 | 20920825 | Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. | Ophthalmology | 2011 | https://conductscience.org/library/papers/20920825 | PubMed |
| 10 | 23901256 | Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). | Clin Ophthalmol | 2013 | https://conductscience.org/library/papers/23901256 | PubMed |
| 11 | 24144450 | Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. | Ophthalmology | 2014 | https://conductscience.org/library/papers/24144450 | PubMed |
| 12 | 23719382 | Control of angiogenesis by AIBP-mediated cholesterol efflux. | Nature | 2013 | https://conductscience.org/library/papers/23719382 | PubMed |
| 13 | 27500363 | Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs. | J Vis Exp | 2016 | https://conductscience.org/library/papers/27500363 | PubMed |
| 14 | 20559689 | Immunohistochemical study of the growth factors, aFGF, bFGF, PDGF-AB, VEGF-A and its receptor (Flk-1) during arteriogenesis. | Mol Cell Biochem | 2010 | https://conductscience.org/library/papers/20559689 | PubMed |
| 15 | 34403208 | Genetic associations of anti-vascular endothelial growth factor therapy response in age-related macular degeneration: a systematic review and meta-analysis. | Acta Ophthalmol | 2022 | https://conductscience.org/library/papers/34403208 | PubMed |
| 16 | 30844038 | Association of CD11b+ Monocytes and Anti-Vascular Endothelial Growth Factor Injections in Treatment of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy. | JAMA Ophthalmol | 2019 | https://conductscience.org/library/papers/30844038 | PubMed |
| 17 | 26614117 | Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis. | Microcirculation | 2016 | https://conductscience.org/library/papers/26614117 | PubMed |
| 18 | 28061854 | Association of statin use and hypertriglyceridemia with diabetic macular edema in patients with type 2 diabetes and diabetic retinopathy. | Cardiovasc Diabetol | 2017 | https://conductscience.org/library/papers/28061854 | PubMed |
| 19 | 30135304 | AIBP augments cholesterol efflux from alveolar macrophages to surfactant and reduces acute lung inflammation. | JCI Insight | 2018 | https://conductscience.org/library/papers/30135304 | PubMed |
| 20 | 4039560 | Cellular mechanisms of resolution of drusen after laser coagulation. An experimental study. | Arch Ophthalmol | 1985 | https://conductscience.org/library/papers/4039560 | PubMed |
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42799766 | Novel semi-automated system for multi-dimensional analysis of macular neovascularization: quantitative biomarkers and rule-based morphological categorization across OCTA platforms. | Graefes Arch Clin Exp Ophthalmol | 2026 | https://conductscience.org/library/papers/42799766 | PubMed |
| 42792595 | Fluid Shear Stress Drives Endothelial Glycolytic Reprogramming via an AIBP/VEGF Axis. | Biology (Basel) | 2026 | https://conductscience.org/library/papers/42792595 | PubMed |
| 42775202 | The CD39-CD73-adenosine axis: a pivotal regulator of retinal homeostasis and diseases. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42775202 | PubMed |
| 42352241 | Ocular Safety of Intravitreal Engineered Humanized Anti-VEGF Nanobody and Its Efficacy in the Attenuation of Choroidal Neovascularization and Associated Subretinal Fibrosis. | Biomolecules | 2026 | https://conductscience.org/library/papers/42352241 | PubMed |
| 42335286 | Nocturnal Intraocular Pressure Monitoring With a Soft Contact Lens Sensor for Glaucoma Management. | Adv Mater | 2026 | https://conductscience.org/library/papers/42335286 | PubMed |
| 42321788 | A novel Tie2xVEGF bispecific antibody fusion demonstrates enhanced therapeutic efficacy through direct Tie2 activation and VEGF neutralization. | J Transl Med | 2026 | https://conductscience.org/library/papers/42321788 | PubMed |
| 42217724 | Murine models of neovascular AMD revisited: Mechanistic pathways, immune-metabolic crosstalk, and the impact of aging and sex. | Exp Eye Res | 2026 | https://conductscience.org/library/papers/42217724 | PubMed |
| 42080790 | Suboptimal Responses to Anti-VEGF in Retinal Neurovascular Diseases: Linking Aging and Alternative Angioinflammatory Pathways. | Invest Ophthalmol Vis Sci | 2026 | https://conductscience.org/library/papers/42080790 | PubMed |
| 42012273 | Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration. | Invest Ophthalmol Vis Sci | 2026 | https://conductscience.org/library/papers/42012273 | PubMed |
| 41658807 | Expert Opinion on the First-Line Management of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in India: The Role of Faricimab. | Cureus | 2026 | https://conductscience.org/library/papers/41658807 | PubMed |
| 41603251 | DNA Nanoflower LYTACs Enable Efficient VEGF Degradation and Verteporfin Loading for Combined Therapy of Wet Age-Related Macular Degeneration. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/41603251 | PubMed |
| 41373488 | Retinal Organoid-Derived Exosomes Reduce CNV Lesion and Restore RPE Integrity in Mouse Laser-Induced Choroidal Neovascularization (CNV) Model. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41373488 | PubMed |
| 41143143 | Faricimab for Refractory Neovascular Age-Related Macular Degeneration: Retrospective Real-World Evidence from India. | Clin Ophthalmol | 2025 | https://conductscience.org/library/papers/41143143 | PubMed |
| 40943417 | From Pathophysiology to Innovative Therapies in Eye Diseases: A Brief Overview. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40943417 | PubMed |
| 40875052 | Morphologic changes of the double-layer sign during anti-vascular endothelial growth factor therapy in eyes with neovascular age-related macular degeneration. | Int Ophthalmol | 2025 | https://conductscience.org/library/papers/40875052 | PubMed |
| 40850787 | Pharmacoproteomics in the development of personalised medicine in Age-related Macular Degeneration (PHARPRO-AMD) study protocol. | BMJ Open Ophthalmol | 2025 | https://conductscience.org/library/papers/40850787 | PubMed |
| 40730279 | Multimodal retinal imaging evaluation of macular degeneration persistent disease activity animal model in Watanabe heritable hyperlipidemic rabbits. | Exp Eye Res | 2025 | https://conductscience.org/library/papers/40730279 | PubMed |
| 40718797 | Targeting retinal angiogenesis: sex differences in adverse reactions to anti-VEGF therapies. | Ther Adv Ophthalmol | 2025 | https://conductscience.org/library/papers/40718797 | PubMed |
| 40710360 | The Long-Standing Problem of Proliferative Retinopathies: Current Understanding and Critical Cues. | Cells | 2025 | https://conductscience.org/library/papers/40710360 | PubMed |
| 40684186 | Recent advances in engineered exosome-based therapies for ocular vascular disease. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/40684186 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38540673
GET https://conductscience.org/api/papers/v1/38540673/references?page=2